Satavaptan treatment for ascites in patients with cirrhosis: a meta-analysis of effect on hepatic encephalopathy development

Satavaptan for the management of ascites in cirrhosis: efficacy and safety across the spectrum of ascites severity

(2011) Florence Wong et al.   GUT

Tolvaptan, an oral vasopressin antagonist, in the treatment of hyponatremia in cirrhosis

(2011) Andrés Cárdenas et al.   JOURNAL OF HEPATOLOGY

Effects of a selective vasopressin V2 receptor antagonist, satavaptan, on ascites recurrence after paracentesis in patients with cirrhosis

(2010) Florence Wong et al.   JOURNAL OF HEPATOLOGY

Risk factors for hepatic encephalopathy in patients with cirrhosis and refractory ascites: relevance of serum sodium concentration

(2010) Mónica Guevara et al.   LIVER INTERNATIONAL

Hyponatremia Is a Risk Factor of Hepatic Encephalopathy in Patients With Cirrhosis: A Prospective Study With Time-Dependent Analysis

(2009) Mónica Guevara et al.   AMERICAN JOURNAL OF GASTROENTEROLOGY

Incidence, Natural History, and Risk Factors of Hepatic Encephalopathy After Transjugular Intrahepatic Portosystemic Shunt With Polytetrafluoroethylene-Covered Stent Grafts

(2008) Oliviero Riggio et al.   AMERICAN JOURNAL OF GASTROENTEROLOGY

Effects of satavaptan, a selective vasopressin V2receptor antagonist, on ascites and serum sodium in cirrhosis with hyponatremia: A randomized trial

(2008) Pere Ginès et al.   HEPATOLOGY

Non-peptide arginine-vasopressin antagonists: the vaptans

(2008) Guy Decaux et al.   LANCET